Identity graph
Ankekang Biopharmaceutical headquarters, locations and relationships
- Legal name
- Sichuan Ankekang Biopharmaceutical Co., Ltd.
- Industry
- Biotechnology
- Founded
- 2018
- Website
- ancocare.com
Ankekang Biopharmaceutical office locations
No office locations recorded yet.
- Parent company
- No parent company recorded in GraphIQ.ai.
Verified from public filings, company websites and news · Methodology
Open in GraphIQ.aiMore Ankekang Biopharmaceutical data in GraphIQ.ai
This page shows the public record. Sign in with a work email to open the rest of the entity.
-
Technographics (available after sign-in)
Software, cloud and infrastructure in use.
-
Firmographics (available after sign-in)
Revenue, headcount, growth and industry codes.
-
Capabilities (available after sign-in)
Products, services and certifications.
-
News (available after sign-in)
Recent coverage and signals, resolved to the entity.
-
And more (available after sign-in)
Subsidiaries, people and lookalike companies.
Who uses the Ankekang Biopharmaceutical entity
-
Revenue and GTM teams
Territories, enrichment and account expansion on one resolved account.
RevOps Sales & marketing -
Industry and supply chain
Suppliers, sites and partners mapped to the right legal entity.
Industry -
Private equity and investors
Corporate family, comparable companies and deal sourcing.
Private equity -
Government and public sector
Supplier vetting, ownership and jurisdiction checks against one verified entity.
Government -
Developers and AI agents
The entity and its relationships through the REST API and MCP server.
Developers
About Ankekang Biopharmaceutical
Ankekang Biopharmaceutical: Pharmaceutical company founded in 2018. Founded in 2018, the company employs approximately 5 people worldwide.
What does Ankekang Biopharmaceutical do?
Ankekang Biopharmaceutical is described as a biotechnology company focused on developing a Flavivirus technology platform and advancing innovative treatments, such as immune oncolytic viruses, replicating nucleic acid drugs, and tumor vaccines. Its goal is to offer new immune oncolytic therapies for cancer patients globally, backed by a core technology platform with independent intellectual property, and encompassing the full industrial chain from preclinical research to production.
One entity, every stage
Put Ankekang Biopharmaceutical to work across your revenue bowtie
- Target Define the market Build the account list from companies shaped like your best customers, Ankekang Biopharmaceutical included. Fingerprint search
- Cover Plan territories Ankekang Biopharmaceutical resolves to one account, so it lands in one territory, once. Territory planning
- Engage Act on timing Leadership changes, funding and M&A arrive linked to the account, not a loose headline. Signal monitoring
- Convert Close on a resolved record Inbound and closed-won attach to one CRM record, with no duplicates to merge. CRM enrichment
- Retain Ground every answer Customer teams and AI agents answer from the same entity, with a source and a date. AI agent data layer
- Expand Find the next buyer inside Follow subsidiaries and divisions to the next team that can buy. Account expansion
About the source
What is GraphIQ.ai?
A B2B identity graph. It resolves each organization into one verified entity and maps its parent and subsidiaries, employees, competitors and news signals. Revenue teams use it in the product; AI agents query it through the REST API and MCP server.
POST/api/v2/organizations/search
Ankekang Biopharmaceutical: frequently asked questions
When was Ankekang Biopharmaceutical founded?
2018.
How many employees does Ankekang Biopharmaceutical have?
About 5, as of October 2026 (GraphIQ.ai estimate).
Questions about GraphIQ.ai
Is GraphIQ.ai a list of companies like a spreadsheet?
No. Each organization resolves to one verified entity linked to its parent, subsidiaries, people and signals, so Ankekang Biopharmaceutical here is the same Ankekang Biopharmaceutical in your CRM, territory plan and agent answers.
Where does this Ankekang Biopharmaceutical data come from?
Public filings, company websites and news, resolved to one entity and continuously updated.